ATXI Avenue Therapeutics

Filed: 21 Sep 21, 8:31am















Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): September 17, 2021


Avenue Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)


(State or Other Jurisdiction
of Incorporation)

(Commission File Number)


(IRS Employer Identification No.)



1140 Avenue of the Americas, Floor 9

New York, New York 10036

(Address of Principal Executive Offices)


(781) 652-4500

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Securities registered pursuant to Section 12(b) of the Exchange Act:


Title of ClassTrading Symbol(s)Exchange Name
Common StockATXINasdaq Capital Market


¨Written communications pursuant to Rule 425 under the Securities Act.
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
¨Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x







Item 8.01.Other Events.


On September 17, 2021, Avenue Therapeutics, Inc. (“Avenue”), received an acknowledgement letter from the Office of New Drugs of the Food and Drug Administration regarding Avenue’s August 31, 2021 Formal Dispute Resolution Request (“FDRR”) concerning complete response letters issued for the New Drug Application (“NDA”) for intravenous (“IV”) tramadol. The letter stated that a response will be provided by October 28, 2021.


The regulatory history of the NDA for IV tramadol, the anticipated FDRR process and other pertinent information regarding these topics were previously disclosed.







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 Avenue Therapeutics, Inc. 
Date: September 21, 2021   
 By:/s/ Lucy Lu, M.D. 
  Lucy Lu, M.D. 
  President and Chief Executive Officer